Antibodies specifically targeting cytoplasmic CD146 have shown possible protective effects both in cancer and vascular diseases [92], as the CD146- Hypoxia-induced factor 1α (HIF-1α) axis has been recently implicated in pulmonary vascular remodeling [93], suggesting a further potential target for pulmonary hypertension treatment. Here, MCAM is linked to cancer.